Vedolizumab for the treatment of ulcerative colitis

Expert Review of Clinical Pharmacology

Volumn 7, Issue 4, 2014, Pages 423-430

  Rietdijk, Svend T ^a   D'haens, Geert R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

inflammatory bowel disease; MAdCAM 1; progressive multifocal leukoencephalopathy; ulcerative colitis; vedolizumab; 4; 7

Indexed keywords

PLACEBO; VEDOLIZUMAB; ANTIBODY; MONOCLONAL ANTIBODY;

ARTICLE; CANCER INFILTRATION; CD4+ T LYMPHOCYTE; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FOLLOW UP; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; DRUG EFFECTS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; HUMANS; LEUKOCYTES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84903200904     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.911084     Document Type: Article

References (71)

1. Rogers BH, Clark LM, Kirsner JB. The epidemiologic and demographic characteristics of inflammatory bowel disease: An analysis of a computerized file of 1400 patients. J Chronic Dis 1971;24: 743-73
2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54. e42-quize30
3. Koloski N-A, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: A critical review of the literature. World J Gastroenterol 2008;14: 165-73 (Pubitemid 351314294
4. Talley NJ, Abreu MT, Achkar J-P, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011;106(Suppl 1): S2-25.quizS26
5. Feagan BG, Macdonald JK. Oral 5-Aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000543
6. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: Current management. J Crohns Colitis 2012;6(10): 991-1030
7. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146(2):392-400
8. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55: 1255-62 (Pubitemid 44277355
9. Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/ monocyte apheresis for active ulcerative colitis. Gastroenterology 2008;135: 400-9
10. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76 (Pubitemid 41770166
11. Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-To-severe ulcerative colitis. Gastroenterology 2012;142:257-65.e1-3
12. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 2011;60:780-7
13. NICE. Available from: Www.nice.org.uk
14. Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: A systematic review and meta-Analysis of population-based studies. Gastroenterology 2013;145:996-1006
15. Danese S. New therapies for inflammatory bowel disease: From the bench to the bedside. Gut 2012;61:918-32
16. Rietdijk ST, D'Haens GR. Recent developments in the treatment of inflammatory bowel disease. J Dig Dis 2013;14:282-7
17. Löwenberg M, D'Haens G. Novel targets for inflammatory bowel disease therapeutics. Curr Gastroenterol Rep 2013;15:311
18. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008;117:244-79
19. Wong M, Ziring D, Korin Y, et al. TNFalpha blockade in human Diseases: Mechanisms and future directions. Clin Immunol 2008;126:121-36
20. Hove ten T, van Montfrans C, Peppelenbosch MP, van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11
21. Van Den Brande JMH, Braat H, van Den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124: 1774-85 (Pubitemid 36666774
22. Shealy D, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2010;2. [Epub ahead of print]
23. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-To-severe ulcerative colitis. Gastroenterology 2014;146(1):85-95
24. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-To-severe ulcerative colitis. Gastroenterology 2014; 146(1):96-109
25. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186:4234-43
26. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367:616-24
27. Mora JR, Bono MR, Manjunath N, et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003;424:88-93 (Pubitemid 36834847
28. Andrew DP, Berlin C, Honda S, et al. Distinct but overlapping epitopes are involved in alpha 4 beta 7-mediated adhesion to vascular cell adhesion molecule-1, mucosal addressin-1, fibronectin, and lymphocyte aggregation. J Immunol 1994;153:3847-61
29. Strauch UG, Lifka A, Gosslar U, et al. Distinct binding specificities of integrins alpha 4 beta 7 (LPAM-1), alpha 4 beta 1 (VLA-4), and alpha IEL beta 7. Int Immunol 1994;6:263-75 (Pubitemid 24055105
30. Newham P, Craig SE, Seddon GN, et al. Alpha4 integrin binding interfaces on VCAM-1 and MAdCAM-1. Integrin binding footprints identify accessory binding sites that play a role in integrin specificity. J Biol Chem 1997;272:19429-40 (Pubitemid 27337741
31. Day ES, Osborn L, Whitty A. Effect of divalent cations on the affinity and selectivity of alpha4 integrins towards the integrin ligands vascular cell adhesion molecule-1 and mucosal addressin cell adhesion molecule-1: Ca2+ activation of integrin alpha4beta1 confers a distinct ligand specificity. Cell Commun Adhes 2002;9:205-19 (Pubitemid 36367406
32. Streeter PR, Berg EL, Rouse BT, et al. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature 1988;331:41-6
33. Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993;74:185-95
34. Briskin MJ, McEvoy LM, Butcher EC. MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1. Nature 1993;363: 461-4 (Pubitemid 23179394
35. Grant AJ, Lalor PF, Hübscher SG, et al. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 2001;33:1065-72 (Pubitemid 32378204
36. Bargatze RF, Jutila MA, Butcher EC. Distinct roles of L-selectin and integrins alpha 4 beta 7 and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: The multistep model confirmed and refined. Immunity 1995;3:99-108
37. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-74 (Pubitemid 32729374
38. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32 (Pubitemid 36026343
39. Sandborn WJ, Colombel J-F, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25 (Pubitemid 41565956
40. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial. Gastroenterology 2007;132: 1672-83 (Pubitemid 46695722
41. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
42. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
43. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23 (Pubitemid 36026342
44. Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol 2011;258:1920-8
45. Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase I study of etrolizumab (rhuMAb b7) in moderate to severe ulcerative colitis. Gut 2013;62: 1122-30
46. Lin KK, Mahadevan U. Etrolizumab: Anti-b7-A novel therapy for ulcerative colitis. Gastroenterology 2014;146:307-9
47. Yu Y, Zhu J, Mi L-Z, et al. Structural specializations of a(4)b(7), an integrin that mediates rolling adhesion. J Cell Biol 2012;196:131-46
48. Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: A randomised study. Gut 2011;60:1068-75
49. Rothlein R, Dustin ML, Marlin SD, Springer TA. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 1986;137:1270-4 (Pubitemid 16041114
50. Dustin ML, Springer TA. Lymphocyte function-Associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1988;107:321-31
51. Nakamura S, Ohtani H, Watanabe Y, et al. In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells. Lab Invest 1993;69:77-85
52. Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120:1339-46 (Pubitemid 32322307
53. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-6 (Pubitemid 34717740
54. Yacyshyn B, Chey WY, Wedel MK, et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007;5:215-20 (Pubitemid 46216935
55. Vegter S, Tolley K, Wilson Waterworth T, et al. Meta-Analysis using individual patient data: Efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. Aliment Pharmacol Ther 2013;38:284-93
56. Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004;19:281-6 (Pubitemid 38253502
57. Soler D, Chapman T, Yang L-L, et al. The binding specificity and selective antagonism of vedolizumab, an anti-Alpha4beta7 integrin therapeutic antibody in Development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330:864-75
58. Fedyk ER, Wyant T, Yang L-L, et al. Exclusive antagonism of the a4 b7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 2012;18:2107-19
59. Haanstra KG, Hofman SO, Lopes Estêväo DM, et al. Antagonizing the a4b1 integrin, but not a4b7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol 2013;190:1961-73
60. Lazarovits AI, Moscicki RA, Kurnick JT, et al. Lymphocyte activation antigens. I. A monoclonal antibody, anti-Act I, defines a new late lymphocyte activation antigen. J Immunol 1984;133:1857-62
61. Schweighoffer T, Tanaka Y, Tidswell M, et al. Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with Hallmarks of gut-Trophism. J Immunol 1993;151:717-29 (Pubitemid 23215737
62. Tidswell M, Pachynski R, Wu SW, et al. Structure-function analysis of the integrin beta 7 subunit: Identification of domains involved in adhesion to MAdCAM-1. J Immunol 1997;159: 1497-505 (Pubitemid 127484131
63. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18:1470-9
64. Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing a4b7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol 2013;264:123-6
65. Feagan BG, McDonald J, Greenberg G, et al. An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). Gastroenterology 2000; 118(4, Suppl 2):A874
66. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-507 (Pubitemid 41007865
67. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710
68. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21
69. Parikh A, Fox I, Leach T, et al. Long-Term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1691-9
70. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-Top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996;111: 1373-80 (Pubitemid 26362264
71. Madara JL, Podolsky DK, King NW, et al. Characterization of spontaneous colitis in cotton-Top tamarins (Saguinus oedipus) and its response to sulfasalazine. Gastroenterology 1985;88:13-19 (Pubitemid 15177634